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Cardiologists are
especially likely to
encounter noncom-
pliance, since it is
particularly preva-
lent with therapies
that are prophylactic
in nature, such as
antihypertensive and
lipid-lowering
agents.
Patients are most
likely to follow a
therapeutic regimen
when the rationale
behind it, the bene-
fits expected, the
potential side effects,
and the importance
of adherence have
been discussed in
detail.As I have written before, the health care community in San Diego has universallycome together for the rather audacious aim of reducing the number of heartattacks and strokes in our county by 50% in 5 years. The basis of this effort is
o have all citizens reach guideline-recommended goals for blood pressure, lipids, and
lood sugar as well as live a healthy lifestyle. In the course of this effort, we have recog-
ized that sustained adherence to medications and lifestyle modification would be re-
uired to achieve our goal. Therefore, as part of our preparations we had a presentation
n patient adherence from a local expert. Although the issue of noncompliance is cer-
ainly not new, I was a bit surprised by the magnitude of the problem, and decided to
ook into it further.
As you may have expected, I found that there is an extensive literature regarding ad-
erence, or the lack thereof. As evidence, there have been a number of Cochrane Sys-
ematic Reviews on the subject over the years (1), and the World Health Organization
ssued a report dealing with it in 2003 (2). Despite the extensive bibliography on the
ubject (3), the issue of adherence is shrouded in uncertainty. To begin with there are
ifferences in definition; noncompliance may be total or partial, the degree of which can
ary between articles, and can even include extra medications. In fact, in an effort to em-
hasize the need for physician–patient collaboration in achieving compliance, the terms
dherence and compliance have been replaced by concordance by a number of authorities.
ethods to identify adherence are also multiple, and often involve imperfect strategies,
uch as testimony from the patient. Although several specific issues are frequently cited
s being responsible, the causes of nonadherence are multiple, and one review indicated
hat as many as 200 potential reasons have been evaluated over the years (4). One classi-
cation that appealed to me was intentional versus unintentional. Data exist to suggest
hat noncompliance results in a suboptimal clinical benefit, a lesser quality of life, and,
f course, a significant waste of resources to the healthcare system. Nevertheless, I was
urprised to find that the most recent systematic review of the subject by Haynes et al.
1) concluded that a clear causal relationship between adherence to therapy and clinical
utcome had yet to be unequivocally established.
Depending upon the definition and the setting, the frequency of noncompliance with
edications varies from 25% to 80%, with a prevalence of 50% being generally accepted
s typical (2). I must admit, I find it hard to believe that one-half of my patients do not
ake their medications as prescribed, but this is likely to be the case. Predictably, a num-
er of factors predispose to a high incidence of nonadherence, including age, underlying
edical condition, psychosocial setting, and the nature of the medication. Cardiologists
re especially likely to encounter noncompliance, since it is particularly prevalent with
herapies that are prophylactic in nature, such as antihypertensive and lipid-lowering
gents (4). There is evidence that even patients who have experienced acute coronary
yndromes and coronary revascularization often fail to follow their recommended treat-
ents. In addition, adherence rates almost invariably fall over time, so that the rate is
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as those often applied for cardiovascular conditions. Obvi-
ously, this is a serious problem that all of us have to deal
with.
As with other aspects of nonadherence, considerable
uncertainty exists regarding remedies. Since there are a
large number of potential causes and conditions that may
influence the problem, it is not surprising that no single
solution has been identified. Several issues are readily ad-
dressed by specific measures. The remedy for the inability
to afford drugs is straightforward, if not easily achieved,
and a variety of devices and strategies are being developed
to deal with the problem of forgetting doses. Simplifying
the number and frequency of pills to be taken is another
obvious tactic to achieve compliance. However, the most
effective approach to the problem involves the interaction
between the patient and the physician. Patients are most
likely to follow a therapeutic regimen when the rationale
behind it, the benefits expected, the potential side effects,
and the importance of adherence have been discussed in
detail. Unfortunately, in the present economic climate the
necessary time and compensation for such discussions is
often lacking.
The issue of nonadherence to therapies has clear signif-
icance for journal editors. JACC, like other journals, re-
eives many manuscripts that use administrative databases.
t is, of course, impossible to know how many patients
ave complied with the medical regimen in these studies.
n fact, even in well-organized prospective trials, docu-
entation of the percent of enrollees that have followed
he prescribed pharmaceutical intervention for the dura-
ion of the protocol may not be reported. While the
ross-over rate is nearly always scrutinized in trials of pro-
edural interventions, the same degree of attention is not
lways given to the potential equivalent of noncompliance
n studies of medications. It can be argued that, despite
he rate of adherence in any study, recommending the
uperior regimen is the strategy that will yield the best
utcome. However, poor compliance may result in the
nability to demonstrate benefit from an effective drug
ompared to placebo, and variable adherence to 2 agents
n a comparative trial can result in misleading findings. It
s obvious, therefore, that adherence is an important vari-
ble to be taken into account by investigators, editors, and
eaders.As have most physicians, I have always been aware of
the issue of nonadherence, and the role it plays in clinical
practice. It has been the cause of hospitalization for many
of the patients admitted to my service, and I have always
taught house officers that patients given 3 or more multi-
ple dose medications daily are likely to fail to follow the
regimen. I must admit, however, that I have probably
underestimated the full dimension of the problem, and
not addressed the issue as seriously as I should. The im-
plications of noncompliance for prophylactic interven-
tions, such as for hypertension or hyperlipidemia, are
enormous and surely will affect the potential to accom-
plish a large reduction in heart attacks and stroke. A
greater appreciation of the role of nonadherence in clini-
cal research is clearly warranted. However, of greatest im-
portance is the effect of noncompliance on the patients
under my care. I still find it hard to accept that 50% of
my patients may not be taking their medications as pre-
scribed. I owe it to them to strive to achieve the highest
adherence possible by whatever means are necessary. De-
termining the best therapy for patients is and will always
be critically important, and has been the primary focus of
my clinical care. Insuring that patients actually take that
therapy is equally important, and will receive equal atten-
tion in my practice from now on.
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